Nkarta Inc Cash Flow Conversion Efficiency
Nkarta Inc cash flow conversion efficiency. Based on the latest financial reports, Nkarta Inc (NKTX) has a cash flow conversion efficiency ratio of -0.098x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.22 Million) by net assets ($247.74 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Nkarta Inc (2018–2025)
Cash flow conversion efficiency of Nkarta Inc from 2018 to 2025. This chart illustrates how Nkarta Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NKTX stock price for real-time trading data and today's change.
Nkarta Inc Cash Flow Conversion Ratio Explained
Nkarta Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Nkarta Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nkarta Inc ranked by their cash flow conversion efficiency. Also see Nkarta Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
D&D Platform Reit Co Ltd
KO:377190
|
N/A |
|
Humanica Public Company Limited
BK:HUMAN
|
0.044x |
|
Vakif Gayrimenkul Yatirim Ortakligi AS
IS:VKGYO
|
0.038x |
|
MAX Automation SE
XETRA:MXHN
|
0.111x |
|
AMREP Corporation
NYSE:AXR
|
0.025x |
|
Idsud S.A
PA:ALIDS
|
-0.907x |
|
Boldt S.A
BA:BOLT
|
0.157x |
|
CANBRIDGE PHARM.DL-00001
F:MF1
|
N/A |
Annual Cash Flow Conversion Efficiency for Nkarta Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Nkarta Inc from 2018 to 2025. Review Nkarta Inc leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $312.32 Million | $-88.70 Million | -0.284x | -16.22% |
| 2024-12-31 | $407.98 Million | $-99.70 Million | -0.244x | +22.49% |
| 2023-12-31 | $273.29 Million | $-86.16 Million | -0.315x | -105.87% |
| 2022-12-31 | $372.21 Million | $-57.00 Million | -0.153x | +43.42% |
| 2021-12-31 | $250.97 Million | $-67.93 Million | -0.271x | -99.84% |
| 2020-12-31 | $321.22 Million | $-43.51 Million | -0.135x | -118.79% |
| 2019-12-31 | $-25.48 Million | $-18.37 Million | 0.721x | -24.97% |
| 2018-12-31 | $-5.40 Million | $-5.18 Million | 0.961x | -- |
About Nkarta Inc
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myo… Read more